{"id":"https://openalex.org/W4362734124","doi":"https://doi.org/10.1016/j.biopsych.2023.02.767","title":"527. GM-2040 is a Novel Putative Non-Hallucinogenic 5-HT2A Agonist With Attenuated Head Twitch and Retained Antidepressant Activity","display_name":"527. GM-2040 is a Novel Putative Non-Hallucinogenic 5-HT2A Agonist With Attenuated Head Twitch and Retained Antidepressant Activity","publication_year":2023,"publication_date":"2023-04-10","ids":{"openalex":"https://openalex.org/W4362734124","doi":"https://doi.org/10.1016/j.biopsych.2023.02.767"},"language":"en","primary_location":{"id":"doi:10.1016/j.biopsych.2023.02.767","doi":"https://doi.org/10.1016/j.biopsych.2023.02.767","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.biopsych.2023.02.767","pdf_url":null,"source":{"id":"https://openalex.org/S205482884","display_name":"Biological Psychiatry","issn_l":"0006-3223","issn":["0006-3223","1873-2402"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological Psychiatry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Adam Klein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Klein","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105990788","display_name":"Eric D. Austin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Austin","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082256940","display_name":"Dino Dvo\u0159\u00e1k","orcid":"https://orcid.org/0000-0003-3884-1393","observed_orcids":["https://orcid.org/0000-0003-3884-1393"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dino Dvorak","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004332028","display_name":"Gerard J. Marek","orcid":"https://orcid.org/0000-0001-8103-4306","observed_orcids":["https://orcid.org/0000-0001-8103-4306"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerard Marek","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jonathan Sporn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Sporn","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022176441","display_name":"L. L. Kiss","orcid":"https://orcid.org/0000-0002-3234-1374","observed_orcids":["https://orcid.org/0000-0002-3234-1374"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laszlo Kiss","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024722202","display_name":"Zo\u00eb A. Hughes","orcid":"https://orcid.org/0000-0001-7174-0944","observed_orcids":["https://orcid.org/0000-0001-7174-0944"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zoe Hughes","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077225690","display_name":"Andrew C. Kruegel","orcid":"https://orcid.org/0000-0002-9156-8755","observed_orcids":["https://orcid.org/0000-0002-9156-8755"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Kruegel","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405267702"],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.05127215,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"93","issue":"9","first_page":"S307","last_page":"S307"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9535999894142151,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9535999894142151,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.03200000151991844,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12553","display_name":"Psychedelics and Drug Studies","score":0.010900000110268593,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/5-ht2a-receptor-agonists","display_name":"5-HT2A receptor agonists","score":0.9160000085830688},{"id":"https://openalex.org/keywords/rapid-acting-antidepressants","display_name":"rapid-acting antidepressants","score":0.8889999985694885},{"id":"https://openalex.org/keywords/antidepressant-effects","display_name":"antidepressant effects","score":0.8629999756813049},{"id":"https://openalex.org/keywords/head-twitches","display_name":"head twitches","score":0.621999979019165}],"concepts":[{"id":"https://openalex.org/C124315065","wikidata":"https://www.wikidata.org/wiki/Q194270","display_name":"Hallucinogen","level":2,"score":0.7778884768486023},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7638914585113525},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.7360498309135437},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6573985815048218},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.49250516295433044},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.35161060094833374},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.34775838255882263},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33601054549217224},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19550061225891113},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.05312752723693848}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.biopsych.2023.02.767","doi":"https://doi.org/10.1016/j.biopsych.2023.02.767","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.biopsych.2023.02.767","pdf_url":null,"source":{"id":"https://openalex.org/S205482884","display_name":"Biological Psychiatry","issn_l":"0006-3223","issn":["0006-3223","1873-2402"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological Psychiatry","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4363648492","https://openalex.org/W4405636586","https://openalex.org/W4415246252","https://openalex.org/W4389164252","https://openalex.org/W3209483485","https://openalex.org/W4292937033","https://openalex.org/W7222785601","https://openalex.org/W2074901757","https://openalex.org/W2322764229","https://openalex.org/W4415182565"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-10T00:00:00"}